Switch theme
Sign up to access all valuation multiples
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
2017
125
LTM Revenue $99.5M
LTM EBITDA -$26.7M
$168M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Maze Therapeutics has a last 12-month revenue (LTM) of $99.5M and a last 12-month EBITDA of -$26.7M.
In the most recent fiscal year, Maze Therapeutics achieved revenue of $168M and an EBITDA of $60.9M.
Maze Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Maze Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $99.5M | XXX | $168M | XXX | XXX | XXX |
| Gross Profit | $87.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$26.7M | XXX | $60.9M | XXX | XXX | XXX |
| EBITDA Margin | -27% | XXX | 36% | XXX | XXX | XXX |
| EBIT | -$26.2M | XXX | $57.6M | XXX | XXX | XXX |
| EBIT Margin | -26% | XXX | 34% | XXX | XXX | XXX |
| Net Profit | -$55.3M | XXX | $52.2M | XXX | XXX | XXX |
| Net Margin | -56% | XXX | 31% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Maze Therapeutics's stock price is $10.
Maze Therapeutics has current market cap of $437M, and EV of $168M.
See Maze Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $168M | $437M | XXX | XXX | XXX | XXX | $-0.76 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Maze Therapeutics has market cap of $437M and EV of $168M.
Maze Therapeutics's trades at 1.0x EV/Revenue multiple, and 2.8x EV/EBITDA.
Equity research analysts estimate Maze Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Maze Therapeutics has a P/E ratio of -7.9x.
See valuation multiples for Maze Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $437M | XXX | $437M | XXX | XXX | XXX |
| EV (current) | $168M | XXX | $168M | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | -6.3x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBIT | -6.4x | XXX | 2.9x | XXX | XXX | XXX |
| EV/Gross Profit | 1.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.9x | XXX | 8.4x | XXX | XXX | XXX |
| EV/FCF | 6.2x | XXX | 2.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMaze Therapeutics's last 12 month revenue growth is -98%
Maze Therapeutics's revenue per employee in the last FY averaged $1.3M, while opex per employee averaged $0.9M for the same period.
Maze Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Maze Therapeutics's rule of X is -272% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Maze Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -98% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -27% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | 476% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -62% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -272% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 50% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 66% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Maze Therapeutics acquired XXX companies to date.
Last acquisition by Maze Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Maze Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Maze Therapeutics founded? | Maze Therapeutics was founded in 2017. |
| Where is Maze Therapeutics headquartered? | Maze Therapeutics is headquartered in United States of America. |
| How many employees does Maze Therapeutics have? | As of today, Maze Therapeutics has 125 employees. |
| Who is the CEO of Maze Therapeutics? | Maze Therapeutics's CEO is Dr. Jason V. Coloma, PhD. |
| Is Maze Therapeutics publicy listed? | Yes, Maze Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Maze Therapeutics? | Maze Therapeutics trades under MAZE ticker. |
| When did Maze Therapeutics go public? | Maze Therapeutics went public in 2025. |
| Who are competitors of Maze Therapeutics? | Similar companies to Maze Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Maze Therapeutics? | Maze Therapeutics's current market cap is $437M |
| What is the current revenue of Maze Therapeutics? | Maze Therapeutics's last 12 months revenue is $99.5M. |
| What is the current revenue growth of Maze Therapeutics? | Maze Therapeutics revenue growth (NTM/LTM) is -98%. |
| What is the current EV/Revenue multiple of Maze Therapeutics? | Current revenue multiple of Maze Therapeutics is 1.7x. |
| Is Maze Therapeutics profitable? | Yes, Maze Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Maze Therapeutics? | Maze Therapeutics's last 12 months EBITDA is -$26.7M. |
| What is Maze Therapeutics's EBITDA margin? | Maze Therapeutics's last 12 months EBITDA margin is -27%. |
| What is the current EV/EBITDA multiple of Maze Therapeutics? | Current EBITDA multiple of Maze Therapeutics is -6.3x. |
| What is the current FCF of Maze Therapeutics? | Maze Therapeutics's last 12 months FCF is $27.1M. |
| What is Maze Therapeutics's FCF margin? | Maze Therapeutics's last 12 months FCF margin is 27%. |
| What is the current EV/FCF multiple of Maze Therapeutics? | Current FCF multiple of Maze Therapeutics is 6.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
